-
Disease Description
Melanoma is considered the most dangerous form of skin cancer. These cancerous growths develop when unrepaired DNA damage to skin cells (most often caused by ultraviolet radiation from sunshine or tanning beds) triggers mutations (genetic defects) that lead the skin cells to multiply rapidly and form malignant tumors. These tumors originate in cells called melanocytes. Melanocytes are the cells responsible for giving our skin their color. Melanomas often resemble moles; some develop from moles. The majority of melanomas are black or brown, but they can also be skin-colored, pink, red, purple, blue or white. Melanoma is caused mainly by intense, occasional UV light exposure (frequently leading to sunburn), especially in those who are genetically predisposed to the disease. [1]
Prevelance
Melanoma is the fifth most common cancer in men and seventh in women in the United States. The number of melanoma cases is increasing faster than for any other type of cancer. Estimates for 2014 are that 76,100 invasive melanomas will be diagnosed in the United States and that melanoma could claim 9710 lives [2].
Current Treatment Options
At present, prevention and early detection are the only effective measures against melanoma. Melanoma basically remains a surgical disease, and excision of thin, biologically early tumors offers the best chance of cure. Despite intensive research, no effective therapies exist for advanced melanoma. Only high-dose IFN -2b has a reproducible benefit in stage II and III patients, but owing to its numerous side effects, modest efficacy, and high cost, it is not used worldwide and is inconsistently used in the United States. For patients with stage IV melanoma, randomized, controlled trials have shown no significant advantage of any specific drug or combination of drugs. Dacarbazine, the only cytotoxic drug approved by the FDA for the treatment of metastatic melanoma, remains the benchmark, but it produces responses of moderate duration and only in a small fraction of the patients. New therapeutic strategies are therefore necessary for the management of melanomas.[3]
Evidence for and the Proposed Mechanism of Cannabinoid Therapeutics
Accumulating recent evidence implicates the endocannabinoid system in the regulation of growth of skin cells. Cannabinoids were also reported to inhibit the growth of melanomas that express cannabinoid receptors (CB1 and CB2) by decreasing growth, proliferation, blood vessel growth and metastasis formation, while increasing cell death. [4]
Groups have studied the potential efficacy of cannabinoids as antitumoral agents against melanoma and showed that these compounds exert a remarkable growth-inhibiting effect on melanoma cells that is evident under various experimental settings (animals with different immune statuses, melanoma cells inoculated at different sites, cannabinoids injected by different routes). Moreover, this is associated with an improvement of various tumor-progression parameters (decreased proliferation and vascularization, increased cell death), as well as with an inhibition of tumor-cell metastatic spreading, one of the clinical hallmarks of advanced melanoma.[5]
Together with the implication of cannabinoid receptors (CB2) in the control of processes such as pain initiation, emesis, and inflammation, opens the attractive possibility of finding cannabinoid-based therapeutic strategies devoid of nondesired psychotropic side effects. Specifically, the antiproliferative effect of cannabinoids reported may set the basis for a new therapeutic approach for the treatment of malignant melanoma.[5]
1. Skin Cancer Foundation. www.skincancer.org/
2. National Cancer Institute. http://seer.cancer.gov/statfacts/html/melan.html
3. Blazquez, C. et al. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633–2635
4. Pacher, P. et al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. Aug 2009; 30(8): 411–420.
5.Blazquez, C. et al. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633–2635
-
Category
Critical Ailments -
Created
Thursday, 16 March 2017 -
Group admin
CBIS
American States University
*** Warning this document contains graphic images.
Click the above Image to Review our Cancer Drug Comparables
Click the above Image to Review our 1-Million Strong FC, Media Kit
*** Warning this document contains exciting images.
Click the surrounding Images to become one of the First 1-Million Strong Killing Cancers, Fight Club Members to help 'Make that Change' Join in Now! *** Warning this Membership contains Exciting Results.
PS ... ALL of our CSi-VIP's, CSi-GIFT Share Recipients (Paid Processing Fees), CSi-Award Recipients, and those who Donated through the GO-Fund-Me Promotion are ALL Automatically included as "1-Million Strong Killing Cancers, Fight Club Members!"
You do not need to purchase anything, you are ALREADY included in the "First" 1-Million Membership Club, CONGRATULATIONS !!!
Please Click the Calendar image below to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
ALL of your PREVIOUS Cannabis Science (CBIS) Shares are on Record with the Company and with the Transfer Agent (As Confirmed by the SEC).
The Company does NOT have your Original trading CBIS Shares, either you have them, or your Brokerage Firm has them (with new identifier codes) or the Transfer Agent has them.
You can confirm with your Broker (Please obtain an Official Brokerage Firm Letter Representing where your CBIS shares are).
Your CBIS GIFT Shares are on Record Books with the Company and/or in your possesion for Regulatory submissions, Registered Legal Opinion Letters, and awaiting Final Audit for Final Trading approvals.
Your CBIS Shares are legal tender and we are ALL waiting for the FINAL Confirmations for trading once the Audits and Legal Filings are completed.
*** We will announce the FINAL CBIS acquisition changes and Corporate Mergers once the filings are completed, so as long as you know where your CBIS Shares are, you are GOOD.
As clearly stated by Mr. Dabney "Our History is Building up into our Inaugural Event of our Lifetime, the Inaugural 1-Million Strong Killing Cancers, Fight Club, VIP Fundraiser Event, dubbed, 'Celebrities Raising $20 Million to Keep Killing Cancers' the Initiative is fueled further with the '1- Million Strong Killing Cancers, Variety Television Show' through the ASU 'Make that Change Campaign'. Hence the accumulation of 1-Million people donating $20 each, because we are ALL Celebrities in our own Rights.
This is More than enough Funding to begin our FDA Clinical Trials for our 'Low-Cost Cancer Drugs' to treat millions Worldwide that already has proven HARVARD Award Winning Cancer Killing Success!
AND
This is also PLENTY of Funding to bring ALL our CBIS Shares back trading again and follow through with our Original Complete Cannabis Science Share trading Game Plan, and We Win, once again. Hopefully we'll see you at the Event to help 'Make that Change'!"
Should you have any further questions regarding your CBIS Shares or additional Share Ownership, Please Click the above Calendar Link to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Observational Studies
Photos
Activity Stream
Still sitting on CBIS shares... what gives?
I periodically check in on this site, but it's so poorly organized that it's impossible to find anything other than Mr. Dabney's cheerleading posts....
Investor Relations
Investor Relations
Adding investor value is of paramount importance to Cannabis Science. One way we do this is to service potential and existing shareholders. We are...
Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"
HARVARD Award Winning
CANCER Killing Success
1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
*** PLUS
(3) other Cannabis Science
REAL WORLD Successes:
Stage 4 Breast Cancer
Skin Cancer
Karposis Sarcoma
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
